NICE shuts down AZ's Tagrisso—and backs Pfizer rival Vizimpro instead
Published on: Monday 08 July 2019
England’s cost watchdogs won’t get behind AstraZeneca blockbuster Tagrisso in previously untreated patients with EGFR-mutated lung cancer. But in a change of events, they’re instead backing a Pfizer challenger.
News source: https://www.fiercepharma.com/pharma/nice-shuts-down-az-s-tagrisso-and-backs-pfizer-rival-vizimpro-instead
